Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58748 | 0.82 | GRM4 (0.45) | GRM4 | |
| SCHEMBL26868296 | 0.80 | GRM4 (0.36) | GRM4 | |
| SCHEMBL28094101 | 0.73 | — | — | |
| SCHEMBL2893689 | 0.72 | GRM4 (0.39) | GRM4 | |
| SCHEMBL24722781 | 0.69 | — | — | |
| SCHEMBL610383 | 0.69 | — | — | |
| SCHEMBL18756768 | 0.69 | — | — | |
| SCHEMBL14420440 | 0.67 | GRM4 (0.41) | GRM4 | |
| SCHEMBL5443031 | 0.67 | GRM4 (0.41) | GRM4 | |
| SCHEMBL14335650 | 0.67 | GRM4 (0.36) | GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106611-A1 | METHOD OF TREATING ACID-BASE DISORDERS | RENIBUS THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-20200054669-A1 | COMPOSITIONS FOR AND METHODS OF TREATING ACID-BASE DISORDERS | TRICIDA, INC. | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054669-A1 | COMPOSITIONS FOR AND METHODS OF TREATING ACID-BASE DISORDERS | SLC10A2, SLC10A1, SLC26A3 | GRM4 1969/4885 |
| US-20210106611-A1 | METHOD OF TREATING ACID-BASE DISORDERS | GLS, ATP6V1B1, SLC10A2 | GRM4 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.